These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 27678443)

  • 61. Obesity, ultrasound indexes of fat depots and lipid goal attainment in patients with high and very high cardiovascular risk: A novel approach towards better risk reduction.
    Haberka M; Okopień B; Gąsior Z
    Nutr Metab Cardiovasc Dis; 2016 Feb; 26(2):123-33. PubMed ID: 26830392
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention.
    Millán J; Pintó X; Muñoz A; Zúñiga M; Rubiés-Prat J; Pallardo LF; Masana L; Mangas A; Hernández-Mijares A; González-Santos P; Ascaso JF; Pedro-Botet J
    Vasc Health Risk Manag; 2009; 5():757-65. PubMed ID: 19774217
    [TBL] [Abstract][Full Text] [Related]  

  • 64. How to assess and manage cardiovascular risk associated with lipid alterations beyond LDL.
    Averna M; Stroes E;
    Atheroscler Suppl; 2017 Apr; 26():16-24. PubMed ID: 28434480
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor? New Insights From the Framingham Offspring Study.
    Bartlett J; Predazzi IM; Williams SM; Bush WS; Kim Y; Havas S; Toth PP; Fazio S; Miller M
    Circ Cardiovasc Qual Outcomes; 2016 May; 9(3):206-212. PubMed ID: 27166203
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Low HDL cholesterol levels in type I Gaucher disease do not lead to an increased risk of cardiovascular disease.
    de Fost M; Langeveld M; Franssen R; Hutten BA; Groener JE; de Groot E; Mannens MM; Bikker H; Aerts JM; Kastelein JJ; Hollak CE
    Atherosclerosis; 2009 May; 204(1):267-72. PubMed ID: 18842264
    [TBL] [Abstract][Full Text] [Related]  

  • 67. ApoB but not LDL-cholesterol is reduced by exercise training in overweight healthy men. Results from the 1-year randomized Oslo Diet and Exercise Study.
    Holme I; Høstmark AT; Anderssen SA
    J Intern Med; 2007 Aug; 262(2):235-43. PubMed ID: 17645591
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, Triglycerides, and Apolipoprotein B and Cardiovascular Risk in Patients With Manifest Arterial Disease.
    van den Berg MJ; van der Graaf Y; de Borst GJ; Kappelle LJ; Nathoe HM; Visseren FLJ;
    Am J Cardiol; 2016 Sep; 118(6):804-810. PubMed ID: 27471056
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Small dense low-density lipoprotein in renal transplant recipients: a potential target for prevention of cardiovascular complications?
    Badiou S; Garrigue V; Dupuy AM; Chong G; Cristol JP; Mourad G
    Transplant Proc; 2006 Sep; 38(7):2314-6. PubMed ID: 16980076
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome.
    Olson EJ; Pearce GL; Jones NP; Sprecher DL
    Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2289-94. PubMed ID: 22814748
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Update on the laboratory investigation of dyslipidemias.
    Ramasamy I
    Clin Chim Acta; 2018 Apr; 479():103-125. PubMed ID: 29336935
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Update on the detection and treatment of atherogenic low-density lipoproteins.
    Sniderman A; Kwiterovich PO
    Curr Opin Endocrinol Diabetes Obes; 2013 Apr; 20(2):140-7. PubMed ID: 23422241
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Discordance between lipoprotein (a) and LDL-cholesterol levels in cardiovascular risk assessment in apparently healthy subjects.
    Bergmann K; Stefanska A; Krintus M; Sypniewska G
    Nutr Metab Cardiovasc Dis; 2023 Jul; 33(7):1429-1436. PubMed ID: 37169665
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Association of Apolipoproteins B and A-1 With Markers of Vascular Health or Cardiovascular Events.
    Zhu YM; Verma S; Fung M; McQueen MJ; Anderson TJ; Lonn EM
    Can J Cardiol; 2017 Oct; 33(10):1305-1311. PubMed ID: 28941609
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Associations of LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B With Cardiovascular Disease Occurrence in Adults: Korean Genome and Epidemiology Study.
    Yun SY; Rim JH; Kang H; Lee SG; Lim JB
    Ann Lab Med; 2023 May; 43(3):237-243. PubMed ID: 36544335
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Apolipoprotein B: Bridging the Gap Between Evidence and Clinical Practice.
    De Oliveira-Gomes D; Joshi PH; Peterson ED; Rohatgi A; Khera A; Navar AM
    Circulation; 2024 Jul; 150(1):62-79. PubMed ID: 38950110
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Apolipoprotein B100 is a better treatment target than calculated LDL and non-HDL cholesterol in statin-treated patients.
    Soran H; France MW; Kwok S; Dissanayake S; Charlton-Menys V; Younis NN; Durrington PN
    Ann Clin Biochem; 2011 Nov; 48(Pt 6):566-71. PubMed ID: 22006975
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Frequency of Attainment of Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol Goals in Cardiovascular Clinical Practice (from the National Cardiovascular Data Registry PINNACLE Registry).
    Spinler SA; Cziraky MJ; Willey VJ; Tang F; Maddox TM; Thomas T; Dueñas GG; Virani SS;
    Am J Cardiol; 2015 Aug; 116(4):547-53. PubMed ID: 26089010
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial).
    Grundy SM; Vega GL; Tomassini JE; Tershakovec AM
    Am J Cardiol; 2009 Aug; 104(4):548-53. PubMed ID: 19660610
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease.
    Mudd JO; Borlaug BA; Johnston PV; Kral BG; Rouf R; Blumenthal RS; Kwiterovich PO
    J Am Coll Cardiol; 2007 Oct; 50(18):1735-41. PubMed ID: 17964036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.